Titre : | Therapeutic potential of 5-HT2C receptor antagonists in the treatment of anxiety disorders |
Auteurs : | M. D. WOOD |
Type de document : | Périodique |
Année de publication : | 2003 |
Format : | 383-387 |
Note générale : |
Current Drug Targets - CNS and Neurological Disorders, 2003, 2, (6), 383-387 |
Langues: | Anglais |
Discipline : | TRA (Traitement et prise en charge / Treatment and care) |
Mots-clés : |
Thésaurus mots-clés SEROTONINE ; RECEPTEUR ; ANTIDEPRESSEURS ; ANTAGONISTE ; ANXIETE ; TRAITEMENT |
Résumé : |
ENGLISH : Anxiety disorders are the most common psychiatric illness affecting both adults and children. Following the observation that m-chlorophenylpiperazine(mCPP) induced anxiety-like states in patients and in animal models, it was shown that in man, mCPP behaves as a functionally selective agonist at the 5-hydroxytryptamine (5-HT)2C receptor. This caused much interest in the development of antagonists at the 5-HT2C receptor for the treatment of anxiety disorders. This review examines the pre-clinical and clinical evidence for a role of the 5-HT2C receptor in anxiety and evaluates the progress of compounds that target this therapeutic approach. (Author' s abstract) |
Domaine : | Hors addiction / No addiction |
Sous-type de document : | Revue de la littérature / Literature review |
Affiliation : |
Psychiatry Centre of Excellence for Drug Discovery, Department of Biology, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW. Email: martyn.wood-1@gsk.com Royaume-Uni. United Kingdom. |
Centre Emetteur : | 13 OFDT |
Cote : | A01986 |
Exemplaires
Disponibilité |
---|
aucun exemplaire |
Accueil